Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin

Mark G. Kris, Steven M. Grunberg, Richard J. Gralla, Lorraine Baltzer, Susan A. Zaretsky, Deborah Lifsey, Leslie B. Tyson, Lisa Schmidt, William F. Hahne

Research output: Contribution to journalArticle

70 Scopus citations

Abstract

Purpose: This dose-ranging trial of intravenous dolasetron mesylate (MDL73, 147EF) was performed to determine its adverse and antiemetic effects in patients receiving cisplatin at doses ≥ 100 mg/m2. Patients and Methods: Eighty-nine patients treated with initial cisplatin received a single intravenous dose of dolasetron mesylate administered over 20 minutes beginning 30 minutes before chemotherapy. The following four dose levels were studied: 1.8, 2.4, 3.0, and 5.0 mg/kg. Emesis and adverse effects were measured for 24 hours after cisplatin. Results: All adverse effects were mild and transient including loose stools, headache, serum AST/ALT elevations, and asymptomatic prolongation of ECG intervals. Among the dose levels, no-emesis rates from 24% to 52% were observed, and the percentage of patients having zero, one, or two emetic episodes ranged from 48% to 82%. Complete control of vomiting increased as the dose was escalated to 2.4 mg/kg, but did not improve further with higher doses. Conclusion: Dolasetron mesylate can be administered safely at doses up to 5.0 mg/kg, with comparable complete protection rates and increased adverse effects at doses greater than 2.4 mg/kg. Antiemetic activity was seen after cisplatin. Trials comparing single infusions of dolasetron mesylate and ondansetron are under way.

Original languageEnglish (US)
Pages (from-to)1045-1049
Number of pages5
JournalJournal of Clinical Oncology
Volume12
Issue number5
DOIs
StatePublished - May 1994

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin'. Together they form a unique fingerprint.

  • Cite this

    Kris, M. G., Grunberg, S. M., Gralla, R. J., Baltzer, L., Zaretsky, S. A., Lifsey, D., Tyson, L. B., Schmidt, L., & Hahne, W. F. (1994). Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. Journal of Clinical Oncology, 12(5), 1045-1049. https://doi.org/10.1200/JCO.1994.12.5.1045